iCell Gene Therapeutics is a biotechnology startup founded in 2014 and headquartered in the United States. The company is focused on developing Chimeric Antigen Receptor (CAR) engineered cells with improved functional properties and expanded applicability. iCell aims to demonstrate clinical proof of concept for unique, patent protected targets and strategies. Their pipeline consists of multiple first-in-man CAR strategies targeting hematological cancers, non-hematological cancers, and autoimmune disorders. As of now, there is no publicly disclosed information about their last investment or the participating investors. With promising advancements in genetic therapeutics, iCell Gene Therapeutics holds potential for significant impact in the biotechnology sector.
iCell Gene Therapeutics
United States
8 employees
Biotechnology
General Information
Get notified when iCell Gene Therapeutics moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track iCell Gene Therapeutics
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biotechnology
About iCell Gene Therapeutics
Taxonomy: Chimeric Antigen Receptor, CAR engineered cells, Clinical-stage biotech, Cancer therapy, Autoimmune disorders, Clinical proof of concept, Hematological cancers, Non-hematological cancers, Cell therapy, Gene therapy, Clinical trials, Patent protection, Immunotherapy, Innovative treatment strategies
No funding data available for iCell Gene Therapeutics yet.
Get notified when iCell Gene Therapeutics raises fundingiCell Gene Therapeutics Alternatives & Competitors
Focused on developing innovative gene therapies for rare diseases.
GigaMune is a therapeutics company developing a novel technology for in vivo, T cell targeted gene d...
Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating hu...
FAQ About iCell Gene Therapeutics
Don't just browse. Track.
Signal Tracker monitors iCell Gene Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
